NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 17 Apr, 2:35PM

58.14

-4.74 (-7.54%)

  • 1D -7.54%
  • 5D -2.95%
  • 1M -14.54%
  • 6M -48.06%
  • YTD -33.57%
  • 1Y -55.00%
  • 5Y 83.32%
Previous Close 62.88
Open 57.91
Volume 27,347,178
Avg. Volume (3M) 8,433,411
Market Cap 261,473,009,664
Price / Earnings (TTM) 16.90
Price / Earnings (Forward) 15.65
Price / Sales 6.59
Price / Book 13.27
52 Weeks Range
57.28 (-1%) — 148.15 (154%)
Earnings Date 7 May 2025
TTM Dividend Yield 2.77%
Profit Margin 34.78%
Operating Margin (TTM) 49.69%
Diluted EPS (TTM) 3.44
Quarterly Revenue Growth (YOY) 30.10%
Quarterly Earnings Growth (YOY) 28.50%
Total Debt/Equity (MRQ) 71.64%
Current Ratio (MRQ) 0.740
Operating Cash Flow (TTM) 120.97 B
Levered Free Cash Flow (TTM) 61.99 B
Return on Assets (TTM) 22.41%
Return on Equity (TTM) 80.77%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Bullish
Drug Manufacturers - General (Global) Bearish Bullish
Stock Novo Nordisk A/S Bearish Bearish

AIStockmoo Score

1.4
Analyst Consensus -0.5
Insider Activity NA
Price Volatility 5.0
Technical Moving Averages 5.0
Technical Oscillators -4.0
Average 1.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 261 B 2.77% 16.90 13.27
LLY 804 B 0.60% 76.66 52.34
MRK 213 B 3.73% 12.31 4.52
NVS 212 B 3.49% 18.03 4.97
JNJ 376 B 3.17% 17.37 4.77
ABBV 311 B 3.64% 72.57 90.53

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Institutions 10.29%

Ownership

Name Date Shares Held
Fayez Sarofim & Co 31 Dec 2024 11,384,481
Everett Harris & Co /Ca/ 31 Dec 2024 6,453,089
52 Weeks Range
57.28 (-1%) — 148.15 (154%)
Median 64.00 (10.08%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
BMO Capital 17 Apr 2025 64.00 (10.08%) Hold 58.08

No data within this time range.

  • 3M
Date Type Details
29 Apr 2025 CNBC Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
25 Apr 2025 CNBC Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
17 Apr 2025 CNBC Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
14 Apr 2025 CNBC Pfizer scraps daily weight loss pill after liver injury in one patient
03 Apr 2025 Announcement Novo Nordisk announces changes in Executive Management
02 Apr 2025 Announcement Lexaria's Human GLP-1 Study #5 Begins Dosing
29 Mar 2025 CNBC Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
29 Mar 2025 Announcement Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
29 Mar 2025 Announcement Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
27 Mar 2025 Announcement Resolutions from the Annual General Meeting of Novo Nordisk A/S
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
24 Mar 2025 Announcement Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
24 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Mar 2025 Announcement The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
20 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
17 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
11 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Mar 2025 Announcement Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
10 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
06 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
05 Mar 2025 Announcement Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
05 Mar 2025 CNBC Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
04 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Mar 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
27 Feb 2025 Announcement Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
27 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
26 Feb 2025 CNBC Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
25 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
20 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
11 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
07 Feb 2025 Announcement Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
06 Feb 2025 Announcement Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
06 Feb 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Feb 2025 CNBC Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
05 Feb 2025 Announcement Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
05 Feb 2025 Announcement Novo Nordisk files annual report with the SEC
05 Feb 2025 CNBC Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Show more
TTM Dividend Yield 2.77%
5Y Average Dividend Yield 2.48%
Payout Ratio 43.78%
Expected Next Dividend Payment Aug 2025
Ex Date Announcement Date Payment Date Details
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Cash
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.10 1 1.89
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria